The Uganda Ministry of Health has taken a significant step towards ending AIDS as a public health threat by 2030, embracing cutting-edge innovations in HIV prevention. Despite making progress in combating HIV, with an HIV prevalence of 5.5% among adults…
“We have seen that people can successfully pick their ARVs from these private pharmacies. So, we think it will be the same with PrEP options,” Kadama said. Read more >>>>>
Uganda is poised to adopt Lenacapavir, a groundbreaking HIV prevention method, following promising results from Gilead Sciences’ PURPOSE 1 trial. The trial, conducted in Uganda and South Africa, demonstrated 100% effectiveness in preventing HIV transmission among women and adolescent girls.…
Lenacapavir, which is administered twice yearly, was subjected to a phase three trial in which 5,300 girls and young women aged 16-25 in Uganda and South Africa participated Read more >>>>>>>>>>>>>>>
After over a decade of working on HIV PrEP trials, it’s extremely fulfilling to get such amazing results from the PURPOSE1 study,” said Dr Flavia Matovu Kiweewa. Read more >>>>>>
The Health Ministry has announced the administration of the first dose of the HIV prevention drug Cabotegravir (Cab-LA) as part of the country’s rollout of long-acting HIV prevention options. Read more >>>>
Twice-Yearly Lenacapavir or Daily Oral Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study Read more >>>>https://www.busogahealthforum.org/download/purpose-1-study-first-phase-3-hiv-prevention-trail-to-show-zero-infections/?wpdmdl=2889&refresh=67307eb1d4b1c1731231409
